SWOT Analysis for Gland Pharma Ltd. - Weakness

Add SWOT widget to your site/app

Buy Zone: Stocks in the buy zone based on days traded at current PE and P/BV

PEG lower than Industry PEG

Dividend yield greater than sector dividend yield

Overbought by Money Flow Index (MFI)

Growth in Net Profit with increasing Profit Margin (QoQ)

Companies with Low Debt

Increasing profits every quarter for the past 2 quarters

Book Value per share Improving for last 2 years

Companies with Zero Promoter Pledge

High Volume, High Gain

Top Gainers

Volume Shockers

Bearish Stocks - Stocks with Medium to Low Trendlyne Momentum Score

Lowest Momentum Scores (Technical Scores)

Stocks with Expensive Valuations according to the Trendlyne Valuation Score

Slowing Down Stocks (DVM)

Inefficient use of capital to generate profits - RoCE declining in the last 2 years

Inefficient use of shareholder funds - ROE declining in the last 2 years

Inefficient use of assets to generate profits - ROA declining in the last 2 years

Declining Net Cash Flow : Companies not able to generate net cash

Annual net profit declining for last 2 years

Weak Momentum: Price below Short, Medium and Long Term Averages

RSI indicating price weakness

Near 52 Week Low

Stocks Underperforming their Industry Price Change in the Quarter

FII / FPI or Institutions increasing their shareholding

MFs decreased their shareholding last quarter

US FDA Warning Letter

Insiders sold stocks

Rising Delivery Percentage Compared to Prev Day

Rising Delivery Percentage Compared to Previous Day and Month, Strong Volumes

Average Financial Performers - Stocks with Medium Trendlyne Durability Score versus Benchmarks

Decline in Quarterly Net Profit with falling Profit Margin (YoY)